Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

2014-08-27 03:16:02 | BioPortfolio


Study AOP 03-007 was designed as a pivotal study to test, if Anagrelide (Thromboreductin®) was not inferior to hydroxyurea (HU) with respect to efficacy in patients with essential thrombocythaemia (ET).

The Anahydret study is a single blind, multi-centre, randomised multinational Phase III Study to compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients with Essential Thrombocythaemia.

The Study starts with a screening visit (visit 1) followed by an induction phase (V2 - V6). During the induction phase, dosing (Anagrelide or Hydroxyurea) is increased or decreased (according to response).

During the maintenance phase (V7 - V14) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.

During maintenance phase efficacy and safety evaluations are performed.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)


Essential Thrombocythemia


Anagrelide, Hydroxyurea


AKH Wien University Clinic for Internal Medicine I, Department of Hematology




AOP Orphan Pharmaceuticals AG

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:16:02-0400

Clinical Trials [297 Associated Clinical Trials listed on BioPortfolio]

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to be produced. Platelets are small cells carried around in the blood, which help form blood clots...

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyur...

Agrylin Drug Use-Result Survey

The objective of this survey is to collect data to evaluate the safety and efficacy of Agrylin (anagrelide hydrochloride) in the post-marketing phase in participants diagnosed with Essenti...

Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia

The hypothesis is that efficient prevention of thrombosis with aspirin at diagnosis becomes less useful once patients have achieved a complete hematologic response (CHR) and/or that this b...

The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET)

Age related differences in response to a drug could arise from variation in pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles between age groups. Whilst the efficacy and safety pro...

PubMed Articles [4444 Associated PubMed Articles listed on BioPortfolio]

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.

First-line cytoreductive drug of choice in high risk essential thrombocythemia (ET) is currently hydroxyurea, a practice based on the results of a randomized study; second-line drugs of choice include...

Anagrelide and the CALR mutation allele burden in essential thrombocythemia.

A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia.

Cytoreductive therapy is used in high-risk essential thrombocythemia (ET) to reduce risk of thrombohemorrhagic complications. Anagrelide is an orally active, quinazolone-derived platelet-lowering agen...

Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.

Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocy...

Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia.

We examined the prognostic factors to validate previous prognostic models for survival and thrombosis with large-scale data on Japanese patients with essential thrombocythemia (ET).

Medical and Biotech [MESH] Definitions

A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Drugs considered essential to meet the health needs of a population as well as to control drug costs. (World Health Organization Action Programme on Essential Drugs, 1994, p3)

Genes whose loss of function or gain of function MUTATION leads to the death of the carrier prior to maturity. They may be essential genes (GENES, ESSENTIAL) required for viability, or genes which cause a block of function of an essential gene at a time when the essential gene function is required for viability.

A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.

More From BioPortfolio on "Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Searches Linking to this Trial